Clinical Trial

Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)

Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of this study is to describe real-world treatment patterns, effectiveness and adverse events of adults diagnosed with schizophrenia that have initiated xanomeline and trospium chloride (KarXT) treatment in the United States
Protocol Amendment History 2 changes
notable Trial sites expanded: 45 -> 52 locations 2026-06-19
notable Trial sites expanded: 32 -> 46 locations 2026-04-14
Trial Details
NCT Number NCT07379827
Lead Sponsor Bristol-Myers Squibb
Conditions Schizophrenia
Enrollment 1,500 participants
Start Date 2026-02-26
Primary Completion 2028-06-20 (estimated)
Study Completion 2028-06-20 (estimated)
Updated on ClinicalTrials.gov 2026-06-18